FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

ATTY, DOCKET NO. 33421-US-PCT APPLICATION NO. 10/574.745 APPLICANT SHETTY ET AL.

Sheet 1 of 1

Group

(Use several sheets if necessary) FILING DATE

U.S. PATENT DOCUMENTS DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATE INITIAL AΑ 2003/162759 8/28/03 Rocha et al. AB 2002/156057 10/24/02 Rubien AC AD AF AF AG AΗ ΑI AJ AK AL FOREIGN PATENT DOCUMENTS TRANSLATION YES NO DOCUMENT NUMBER DATE OFFICE CLASS SUBCLASS AM 0.831.910 B 11/21/01 Europe AΝ AΩ AP П ΑO П OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Pitt et al., "The Effect of Spironolactione on Morbidity and Mortality in Patients with Severe Heart Failure," New England Journal of Medicine, The Massachusetts Medical Society, Vol. 341, No. 10, pp. AR 709-717 (1999) Sawathiparnich et al., "Effect of combined AT1 receptor and aldosterone receptor antagonism on AS plasminogen activator inhibitor-1," Journal of Clinical Endocrinology and Metabolism, Vol. 88, No. 8, pp. 3867-3873 (2003) Pitt et al., "Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients with Essential AΤ Hypertension and Left Ventricular Hypertrophy. The 4E-Left Ventricular Hypertrophy Study. Circulation, pp. 1831-1838 (2003) EXAMINER DATE CONSIDERED /Samira Jean-louis/ 11/21/2009

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 809. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.